{"id":"NCT02201290","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","officialTitle":"An Extension Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenia Purpura (ITP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-18","primaryCompletion":"2017-07-04","completion":"2017-07-04","firstPosted":"2014-07-28","resultsPosted":"2019-07-05","lastUpdate":"2019-07-05"},"enrollment":9,"design":{"allocation":null,"model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Purpura, Thrombocytopenic, Idiopathic"],"interventions":[{"type":"DRUG","name":"Eltrombopag Tablets","otherNames":[]},{"type":"DRUG","name":"Eltrombopag PfOS","otherNames":[]}],"arms":[{"label":"Eltrombopag","type":"EXPERIMENTAL"}],"summary":"This was an open-label Phase III extension study to evaluate the long-term safety of eltrombopag in pediatric patients with chronic ITP who previously participated in study TRA115450. This study allowed dosing of eltrombopag at an individualized dose for each subject based upon platelet count. The starting dose was based on the subject's dose at the end of the TRA115450 study. The maximum dose was 75 mg daily.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"Up to week 4 follow up period","effectByArm":[{"arm":"Eltrombopag","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":2},"locations":{"siteCount":3,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":9},"commonTop":["Nasopharyngitis","Headache","Pharyngitis","Tonsillitis","Blood bilirubin increased"]}}